The ontogenic changes in thyroxine 5′-monodeiodinase (5′-MD) activity were examined in brown adipose tissue (BAT) of fetal (26, 28 and 30 days of gestation) and newborn (1–14 days old) rabbits. A near-maximum stimulation of BAT 5′-MD activity was reached at 1 mM of dithiothreitol (DTT). The kinetics of 5′-MD inhibition by propylthiouracil (PTU) was uncompetitive in fetal and noncompetitive in neonatal tissue. In fetal tissue the Ki was 3.2 mM independently of DTT concentration, in newborns from 0.5 to 8.25 mM at 1–10 mM of DTT. An apparent Km constant for T4 to T3 conversion in BAT of fetal rabbit amounted to 0.2, 0.67, 1.9 and 2.0 μM in the presence of 1, 2, 5 and 10 mM DTT, respectively. In neonatal rabbits Km was constant (0.72 μM) in various DTT concentrations. The presence of 5′-MDI and 5′-MDII in BAT of fetal and neonatal rabbit was identified. Using iopanoic acid and amiodarone as inhibitors, a decrease in the 5′-MDII:5′-MDI ratio from 8.9 to 2.7 after birth was observed. Changes in 5′-MD activity with advancing age were not correlated with the SH group content in the BAT.

Keywords:
5′-Monodeiodinase inhibition, ontogenesis, T4 conversion, Triiodothyronine, Fetal rabbits, Newborn rabbits, Brown adipose tissue
This content is only available via PDF.
© 1990 S. Karger AG, Basel
1990
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.